The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF.
Moreover several secondary objectives will be investigated.
Age of 18 years or older
Capable of understanding and signing informed consent
A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.
History of LVEF ≤40%
Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
Impaired renal function, defined as eGFR < 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
Patients with a (suspected) diagnosis of HFpEF will be recruited through the Cardiology outpatient clinics of the Erasmus MC and five other hospitals.
Cohort
Prospective
Not listed
The primary endpoint is the number of participants with a combined endpoint of: urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and cardiovascular death.
This is a composite endpoint; therefore, the first occurrence of any of the described components will result in the endpoint being met for an individual patient.
Number of participants with urgent visit resulting in intravenous therapy for heart failure
Number of patients with hospital readmission for acute or worsened HF
Number of participants with cardiovascular death.
Number of participants with the combined endpoint urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and all-cause death.
This is a composite endpoint; therefore, the first occurrence of any of the described components will result in the endpoint being met for an individual patient.
Click on the lead sponsor to view all of their trials.
Erasmus Medical Center
Lead sponsor
Ikazia Hospital, Rotterdam
Collaborator
Franciscus Gasthuis & Vlietland (Hospital)
Collaborator
OLVG
Collaborator
Universitair Ziekenhuis Brussel
Collaborator
Noordwest Ziekenhuisgroep
Collaborator
